AstraZeneca spinoff Viela Bio has gone public in an offering that involved existing backers buying some $70m worth of stock, and its share price has since risen 21.7%.

US-based autoimmune and severe inflammatory disease drug developer Viela Bio has floated in a $150m initial public offering after being spun off by pharmaceutical company AstraZeneca in 2018. The offering consisted of 7.9 million shares issued on the Nasdaq Global Select Market on Thursday. The company increased the number of shares from 7.5 million but…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.